1. Shelley W, Crissey J. In: Wilan R, editor. Classics in Clinical Dermatology. Springfield (IL): C.C Thomas. 1970; p. 17.
2. Scully C, Challacombe SJ. Pemphigus Vulgaris: Update on Etiopathogenesis, Oral Manifestations and Management. Crit Rev Oral Biol Med. 2002; 13 (5): 397-408.
3. Greenberg MS. Ulcerative, Vesicular and Bullous Lesions. In: Greenberg MS, Glick M, eds. Burket's Oral Medicine, ed 10. Ontorio: BC Decker, 2003; p. 50-84.
4. Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, Izumi H, Ratrie H 3rd, Mutasim D, Ariss-Abdo L, et al. Paraneoplastic Pemphigus: An Autoimmune Mucocutaneous Disease Associated with Neoplasia. N Engl J Med, 1990; 323: 1729-35.
5. Sklavounou A, Laskaris G. Paraneoplastic Pemphigus: A Review. Oral Oncol, 1998; 35:437-40.
6. Nishikawa T, Hashimoto T, Shimizu H, Ebihara T, Amagai M. Pemphigus: from Immunofluorescence to Molecular Biology. J Dermatol Sci, 1996; 12: 1-9.
7. Becker BA, Gaspari AA. Pemphigus Vulgaris and Vegetans. Dermatol Clin, 1993; 11: 453-62.
8. Field A, Longman L, Tyldesley WR. Tyldesley's Oral Medicine, ed 5. New York: Oxford, 2003; p. 125-39.
9. Laskaris G, Stoufi E. Oral Pemphigus Vulgaris in a 6-Year-Old Girl. Oral Surg Oral Med Oral Pathol. 1990; 69: 609-13.
10. Eller J, Kest L. Pemphigus: Repon of Seventy-Seven Cases. Arch Dermatol. 1941; 44: 337-44.
11. Gellis S, Glass F. Pemphigus, a Survey of One Hundred and Seventy Patients Admitted to Bellevue Hospital from 1911-1941. Arch Dermatol, 1941; 44: 321-36.
12. Pisanti S, Sharav Y, Kaufman E, Posner LN. Pemphigus Vulgaris: Incidence in Jews of different ethnic groups, according to age. sex and initial lesion. Oral Surg Oral Med Oral Pathol, 1974; 38: 382-7.
13. Krain LS, Terasaki PI, Newcomer VD, Mickey MR. Increased Frequency of HLA-A10 in Pemphigus Vulgaris. Arch Dermatol, 1973; 108: 803-5.
14. Park MS, Terasaki PI, Ahmed AR, Tiwari JL. HLA-DRW4 in 91% of Jewish Pemphigus Vulgaris Patients. Lancet, 1979; 2: 441-2.
15. Tron F, Gilbert D, Mouquet H, Joly P. Drouot L, Makni S, Masmoudi H, Charron D, Zitouni M, Loiseau P, Ben Ayed M. Genetic Factors in Pemphigus. J Autoimmun, 2005; 24 (4): 319-28.
16.
Tanyeri H. Oral Mukozanın İmmünolojik Hastalıkları ve Tedavileri. İstanbul: Nobel, 2000; s. 69-75.
17. Ruocco E, Baroni A, Wolf R. Vincenzo R. Life-Threatening Bullous Dermatoses: Pemphigus Vulgaris. Clin Dermatol, 2005; 23 (3): 223-6.
18.
Ünür M, Doğan Onur O. Ağız Hastalıklarının Teşhis ve Tedavisi. İstanbul: Quintessence, 2003; s. 223-5.
19. Lewinson W. Jawetz E. Medical Microbiology & Immunology: Examination & Board Review, ed 7. San Francisco:McGraw-Hill. 2002; p. 427.
20.
Yücetaş Ş. Ağız ve Çevre Dokusu Hastalıkları. Ankara: Atlas, 2005; s. 366-7.
21.
Özbayrak S. Ağız Hastalıkları Atlası: Tanı Kriterleri, Ayırıcı Tanı ve Tedavi Yaklaşımları. İstanbul: Quintessence, 2003; s. 68-9.
22.
Cünhan Ö. Oral ve Maksillofasiyal Patoloji. Ankara: Atlas, 2001; s. 27, 59-83.
23. Sirois DA. Fatahzadeh M, Roth R, Etlin D. Diagnostic Patterns and Delays in Pemphigus Vulgaris: Experience with 99 Patients. Arch Dermatol, 2000; 136(12): 1569-70.
24. Ahmed AR, Graham J, Jordan RE, Provost TT. Pemphigus: Current Concepts. Ann Intern Med, 1980; 92: 396-405.
25. Stoopler ET, Sollecito TP, DeRossi SS. Desquamative Gingivitis: Early Presenting Symptom of Mucocutaneous Disease. Quintessence Int, 2003; 34 (8): 582-586.
26. Mariotti A. Desquamative Gingivitis: Revisited. Todays FDA, 1991:3: 1C-2C.
27. Henry JB. Clinical Diagnosis and Management by Laboratory Methods, ed 20. Philadelphia: WB Saunders, 2001; p. 1002.
28. Ünür M, Büyükbabani N, Bektaş K, Demirez E. Pemfigus Vulgariste Öncü Ağız Lezyonlan. Akademik Dental Dişhekimliği Dergisi, 2003; 5 (3): 28-31.
29. Nousari CH, Brodsky R, Anhalt GJ. Evaluating the Role of Immunoablative High-Dose Cyclophosphamide Therapy in Pemphigus Vulgaris. J Am Acad Dermatol, 2003;49:148-150.
30. Mignogna MD, Lo Muzio L. Ruoppo E, Fedele S, Lo Russo L, Bucci E. High-Dose Intravenous 'Pulse' Methylprednisolone in the Treatment of Severe Oropharyngeal Pemphigus: a Pilot Study. J Oral Pathol Med, 2002; 31 (6): 339-344.
31. Ahmed AR, Dahi MV. Consensus Statement on the Use of Intravenous Immunoglobulin Therapy in the Treatment of Autoimmune Mucocutaneous Blistering Diseases. Arch Dermatol, 2003; 139 (8): 1051-9.
42
Zeynep BOY, Kıvanç BEKTAŞ, Meral ÜNÜR
32. Ruocco V, Rossi A, Argenziano G. Aatarita C, Alviggi L, Farzati B, Papaleo G. Pathogenicity of the Intercellular Antibodies of Pemphigus and their Periodic Removal from the Circulation by Plasmapheresis. Br J Dermatol, 1978; 98 (2): 237¬41.
33. Lüftl M, Stauber A, Mainka A, Klingel R, Schuler G, Hertl M. Successful Removal of Pathogenic Autoantibodies in Pemphigus by Immunoadsorption with a Tryptophan-linked Polyvinylalcohol Adsorber. Br J Dermatol, 2003; 149 (3): 598-605.
34. Zegarelli DJ, Zegarelli EV. Intraoral Pemphigus Vulgaris. Oral Surg, 1977; 44: 384.
35. Kanwar J, Dhar S. Factors Responsible for Death in Patients with Pemphigus. J Dermatol. 1994; 21: 655¬9.
36. Savin J. Corticosteroids and Death in Pemphigus. J Am Acad Dermatol, 1983; 9 (2): 275.
37. Mutasim DF. Managament of Autoimmune Bullous Diseases: Pharmacology amd Therapeutics. J Am Acad Dermatol, 2004; 51: 859-77.
38. Robinson JC, Lozada-Nur F, Frieden I. A Review of the Literature and a Report on the Management of 12 Cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 1997; 84: 349-55.
39. Lozada-Nur F, Miranda C, Maliksi R. Double-Blind Clinical Trial of 0.05% Clobetasol Propionate Ointment in Orabase and 0.05% Fluocinonide Ointment in Orabase in the Treatment of Patients with Oral Vesiculoerosive Diseases. Oral Surg Oral Med Oral Pathol, 1994; 77: 598-604.
40. Pierard GE. Pierard-Franchimont C, Ben Mosbah T, Arrese Estrada J. Adverse Effects of Topical Corticosteroids. Acta Derm Venereol. Suppl (Stockh), 1989; 151: 26-30: discussion 47-52.
41. Weinberg MA, Insler MS, Campen RB. Mucocutaneous Features of Autoimmune Blistering Diseases. Oral Med Oral Pathol Oral Radiol Endod. 1997; 84 (5): 517-34.
Thank you for copying data from http://www.arastirmax.com